These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 24464355)

  • 1. Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors.
    Inada-Inoue M; Ando Y; Kawada K; Mitsuma A; Sawaki M; Yokoyama T; Sunakawa Y; Ishida H; Araki K; Yamashita K; Mizuno K; Nagashima F; Takekura A; Nagamatsu K; Sasaki Y
    Cancer Chemother Pharmacol; 2014 Apr; 73(4):673-83. PubMed ID: 24464355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors.
    de Jonge MJ; Hamberg P; Verweij J; Savage S; Suttle AB; Hodge J; Arumugham T; Pandite LN; Hurwitz HI
    Invest New Drugs; 2013 Jun; 31(3):751-9. PubMed ID: 23054212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors.
    Henary H; George GC; Wheler J; Naing A; Piha-Paul S; Fu S; Mistry R; Zinner R; Kurzrock R; Hong DS
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):597-603. PubMed ID: 26210681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.
    Monk BJ; Mas Lopez L; Zarba JJ; Oaknin A; Tarpin C; Termrungruanglert W; Alber JA; Ding J; Stutts MW; Pandite LN
    J Clin Oncol; 2010 Aug; 28(22):3562-9. PubMed ID: 20606083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors.
    Infante JR; Novello S; Ma WW; Dy GK; Bendell JC; Huff A; Wang Q; Suttle AB; Allen R; Xu CF; Ottesen LH; Burris HA; Adjei AA
    Invest New Drugs; 2013 Aug; 31(4):927-36. PubMed ID: 23179337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.
    Cristofanilli M; Johnston SR; Manikhas A; Gomez HL; Gladkov O; Shao Z; Safina S; Blackwell KL; Alvarez RH; Rubin SD; Ranganathan S; Redhu S; Trudeau ME
    Breast Cancer Res Treat; 2013 Jan; 137(2):471-82. PubMed ID: 23239151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib.
    Dy GK; Infante JR; Eckhardt SG; Novello S; Ma WW; Jones SF; Huff A; Wang Q; Suttle AB; Ottesen LH; Adjei AA; Burris HA
    Invest New Drugs; 2013 Aug; 31(4):891-9. PubMed ID: 23135778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies.
    Tan AR; Dowlati A; Stein MN; Jones SF; Infante JR; Bendell J; Kane MP; Levinson KT; Suttle AB; Burris HA
    Br J Cancer; 2014 May; 110(11):2647-54. PubMed ID: 24800949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors.
    Kummar S; Srivastava AK; Navas T; Cecchi F; Lee YH; Bottaro DP; Park SR; Do KT; Jeong W; Johnson BC; Voth AR; Rubinstein L; Wright JJ; Parchment RE; Doroshow JH; Chen AP
    Invest New Drugs; 2021 Dec; 39(6):1577-1586. PubMed ID: 34180036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors.
    Plummer R; Madi A; Jeffels M; Richly H; Nokay B; Rubin S; Ball HA; Weller S; Botbyl J; Gibson DM; Scheulen ME
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):93-101. PubMed ID: 23064954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study.
    Hamberg P; Boers-Sonderen MJ; van der Graaf WT; de Bruijn P; Suttle AB; Eskens FA; Verweij J; van Herpen CM; Sleijfer S
    Br J Cancer; 2014 Feb; 110(4):888-93. PubMed ID: 24366297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.
    Simonelli M; Zucali PA; Lorenzi E; Rubino L; De Vincenzo F; De Sanctis R; Perrino M; Mancini L; Di Tommaso L; Rimassa L; Masci G; Zuradelli M; Suter MB; Bertossi M; Fattuzzo G; Giordano L; Roncalli MG; Santoro A
    Eur J Cancer; 2013 Mar; 49(5):989-98. PubMed ID: 23146956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors.
    Kendra KL; Plummer R; Salgia R; O'Brien ME; Paul EM; Suttle AB; Compton N; Xu CF; Ottesen LH; Villalona-Calero MA
    Mol Cancer Ther; 2015 Feb; 14(2):461-9. PubMed ID: 25504632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of pazopanib administered in combination with bevacizumab.
    Imbs DC; Négrier S; Cassier P; Hollebecque A; Varga A; Blanc E; Lafont T; Escudier B; Soria JC; Pérol D; Chatelut E
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1189-96. PubMed ID: 24705975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma.
    Reardon DA; Groves MD; Wen PY; Nabors L; Mikkelsen T; Rosenfeld S; Raizer J; Barriuso J; McLendon RE; Suttle AB; Ma B; Curtis CM; Dar MM; de Bono J
    Clin Cancer Res; 2013 Feb; 19(4):900-8. PubMed ID: 23363814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer.
    Johnston SR; Gómez H; Stemmer SM; Richie M; Durante M; Pandite L; Goodman V; Slamon D
    Breast Cancer Res Treat; 2013 Feb; 137(3):755-66. PubMed ID: 23283526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I Study of Pazopanib and Ixabepilone in Patients With Solid Tumors.
    Ganesan C; Obulareddy SJ; Fischer JH; Antonysamy MA; Jha G; Bliss RL; Dudek AZ
    Am J Clin Oncol; 2016 Jun; 39(3):280-7. PubMed ID: 24577167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of pazopanib in patients with advanced cancer.
    Hurwitz HI; Dowlati A; Saini S; Savage S; Suttle AB; Gibson DM; Hodge JP; Merkle EM; Pandite L
    Clin Cancer Res; 2009 Jun; 15(12):4220-7. PubMed ID: 19509175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors.
    Tan AR; Gibbon DG; Stein MN; Lindquist D; Edenfield JW; Martin JC; Gregory C; Suttle AB; Tada H; Botbyl J; Stephenson JJ
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1635-43. PubMed ID: 23636448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of pazopanib plus TH-302 in advanced solid tumors.
    Riedel RF; Meadows KL; Lee PH; Morse MA; Uronis HE; Blobe GC; George DJ; Crawford J; Niedzwiecki D; Rushing CN; Arrowood CC; Hurwitz HI
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):611-619. PubMed ID: 28238078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.